Progress on Phage Display Technology: Tailoring Antibodies for Cancer Immunotherapy

Area of Science:

• Immunology
• Biotechnology
• Oncology

Background:

• Antibodies are crucial for cancer therapy, but developing non-immunogenic human antibodies is challenging.
• Traditional hybridoma technology has limitations for generating human anti-cancer antibodies.
• Phage display offers an alternative for selecting human antibodies against specific cancer targets.

Purpose of the Study:

• To review the progress and strategies in using phage display for anti-cancer antibody development.
• To highlight the potential of phage display-derived antibodies in various therapeutic formats.
• To discuss advancements in antibody selection and refinement for targeted cancer therapies.

Main Methods:

• Utilizing genetically engineered phages in libraries to display antibody fragments (scFv, Fab).
• In vitro selection of novel antibody molecules directed against cancer antigens.
• Reviewing clinical progression and evaluation of phage display-derived antibodies.

Main Results:

• Phage display facilitates the selection of human monoclonal antibodies, bypassing immunogenicity issues.
• Several phage display-derived antibodies are now in clinical trials or evaluation.
• Advanced antibody formats like CAR T-cell therapy and antibody-drug conjugates are being developed.

Conclusions:

• Phage display is a powerful tool for generating targeted anti-cancer antibodies.
• This technology enables the development of novel therapeutic strategies, including antibody-drug conjugates and CAR T-cell therapies.
• Continued innovation in phage selection and antibody refinement promises expanded therapeutic options for cancer patients.